Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Inflammatory Bowel Diseases

Free Subscription Articles published in Eur J Gastroenterol Hepatol Retrieve available abstracts of 90 articles: HTML format

Single Articles

August 2025
1. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo S
   Letter to the editor regarding 'First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn's disease'.
   Eur J Gastroenterol Hepatol. 2025;37:985-986.
   PubMed    
   
   
   
2. RIVA A, Arienti G, Zuin G, Spini L, et al
   Psychological symptoms and alexithymia in adolescents with inflammatory bowel diseases: a case-control study.
   Eur J Gastroenterol Hepatol. 2025;37:917-921.
   PubMed     Abstract available
   
   
   June 2025
3. DI PAOLO MC, Cassinotti A, Pagnini C, Ceccarelli L, et al
   Adherence to clinical and endoscopic standards of quality in inflammatory bowel disease: a nationwide survey from the Italian Association of Hospital Gastroenterologists and Endoscopists.
   Eur J Gastroenterol Hepatol. 2025 Jun 26. doi: 10.1097/MEG.0000000000003025.
   PubMed     Abstract available
   
   
   
4. PUGLIESE N, Bezzio C, Festa S, Caprioli FA, et al
   Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey.
   Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003016.
   PubMed     Abstract available
   
   
   
5. COUTO SOUSA D, Fernandes SR, Saraiva S, Goncalves AR, et al
   Outcomes of acute severe ulcerative colitis at initial presentation.
   Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003015.
   PubMed     Abstract available
   
   
   
6. CROSEWSKI NI, Pereira AHM, Kotze LR, Pedroso MLA, et al
   Hepatotoxicity associated with vedolizumab: case report in a patient with ulcerative colitis.
   Eur J Gastroenterol Hepatol. 2025 Jun 18. doi: 10.1097/MEG.0000000000003022.
   PubMed     Abstract available
   
   
   May 2025
7. SCALVINI D, Bezzio C, Maimaris S, Lenti MV, et al
   A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting.
   Eur J Gastroenterol Hepatol. 2025 May 19. doi: 10.1097/MEG.0000000000003005.
   PubMed     Abstract available
   
   
   
8. SZLAK J, Magdziak A, Mroz A, Wieszczy-Szczepanik P, et al
   Cytomegalovirus infection in patients with active ulcerative colitis: a prospective observational study.
   Eur J Gastroenterol Hepatol. 2025 May 12. doi: 10.1097/MEG.0000000000003001.
   PubMed     Abstract available
   
   
   
9. MORGAN M, Loel B, Lang R, Reilly C, et al
   The use of oral antibiotic cocktail in medically refractory paediatric acute severe colitis: a case series.
   Eur J Gastroenterol Hepatol. 2025;37:594-599.
   PubMed     Abstract available
   
   
   April 2025
10. COLWILL M, Baillie S, Radia C, White S, et al
    The impact of ethnicity on delays in initiating advanced therapy for inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2025 Apr 30. doi: 10.1097/MEG.0000000000002995.
    PubMed     Abstract available
    
    
    March 2025
11. GATT Y, Chatlani D, Camilleri C, Sciberras M, et al
    The role of chest X-ray in detecting latent tuberculosis among patients with low-risk inflammatory bowel disease before advanced therapy.
    Eur J Gastroenterol Hepatol. 2025 Mar 26. doi: 10.1097/MEG.0000000000002975.
    PubMed     Abstract available
    
    
    
12. PATRA S, Chaudhary S, Samal SC, Ayyanar P, et al
    FoxP3-positive T regulatory cells and its effector mechanisms in Crohn's disease: an immunohistochemical and image morphometric analysis on endoscopic mucosal biopsies.
    Eur J Gastroenterol Hepatol. 2025 Mar 24. doi: 10.1097/MEG.0000000000002971.
    PubMed     Abstract available
    
    
    
13. YUKSEL I, Cagir Y, Durak MB, Atay A, et al
    A comparison between the Bowel Ultrasound Score and International Bowel Ultrasound Segmental Activity Score based on ileocolonoscopy in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2025 Mar 18. doi: 10.1097/MEG.0000000000002969.
    PubMed     Abstract available
    
    
    
14. GODOY FINGER AP, Tavares Ferreira de Oliveira Cruz L, Rosevics L, de Queiroz-Telles F, et al
    Management of sporotrichosis in patients with inflammatory bowel disease using biological therapy (antitumor necrosis factor).
    Eur J Gastroenterol Hepatol. 2025;37:370-375.
    PubMed     Abstract available
    
    
    
15. HANZEL J, Novak G, Jairath V, Zou G, et al
    Directionality of endoscopic and histologic healing in ulcerative colitis: a prospective pilot study.
    Eur J Gastroenterol Hepatol. 2025;37:304-307.
    PubMed     Abstract available
    
    
    
16. TE GROEN M, Derks MEW, Nagtegaal ID, Peters CP, et al
    Gastrointestinal pathologist consensus of revised high-grade dysplasia in inflammatory bowel disease impacts the advanced neoplasia rate: a multicenter study.
    Eur J Gastroenterol Hepatol. 2025;37:287-294.
    PubMed     Abstract available
    
    
    February 2025
17. JANSEN FM, den Broeder N, van Hal TW, Mahler EAM, et al
    Characteristics, risk factors, and disease course of musculoskeletal manifestations in patients with inflammatory bowel disease: a prospective longitudinal cohort study.
    Eur J Gastroenterol Hepatol. 2025 Feb 21. doi: 10.1097/MEG.0000000000002921.
    PubMed     Abstract available
    
    
    
18. OJAGHI SHIRMARD F, Pourfaraji SM, Saeedian B, Bagheri T, et al
    The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2025 Feb 18. doi: 10.1097/MEG.0000000000002952.
    PubMed     Abstract available
    
    
    
19. SUPOVEC E, Hanzel J, Novak G, Manevski D, et al
    First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn' disease, but not in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2025 Feb 6. doi: 10.1097/MEG.0000000000002940.
    PubMed     Abstract available
    
    
    
20. MOLANDER P, Af Bjorkesten CG, Henricson H, Koskela R, et al
    Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study.
    Eur J Gastroenterol Hepatol. 2025 Feb 5. doi: 10.1097/MEG.0000000000002939.
    PubMed     Abstract available
    
    
    
21. BASSOTTI G, Del Sordo R, Lanzarotto F, Mino S, et al
    Claudin-2 simplifies histological assessment of activity/remission of ulcerative colitis in real-life daily practice.
    Eur J Gastroenterol Hepatol. 2025 Feb 4. doi: 10.1097/MEG.0000000000002938.
    PubMed     Abstract available
    
    
    
22. ZARKER AW, Wang Y
    Combination vedolizumab and ustekinumab for refractory Crohn's disease after immune checkpoint inhibitors.
    Eur J Gastroenterol Hepatol. 2025;37:240-241.
    PubMed    
    
    
    January 2025
23. LIATSOS C, Tzouvala M, Michalopoulos G, Giouleme O, et al
    Efficacy and safety of tofacitinib for the treatment of moderate-to-severe ulcerative colitis in biologic-naive patients.
    Eur J Gastroenterol Hepatol. 2025 Jan 23. doi: 10.1097/MEG.0000000000002926.
    PubMed     Abstract available
    
    
    
24. KOHLI I, Thind N, Bhalla A, Attri A, et al
    Sarcopenia is associated with worse outcomes in patients with inflammatory bowel disease: insights from US national hospitalization data.
    Eur J Gastroenterol Hepatol. 2025;37:55-61.
    PubMed     Abstract available
    
    
    
25. ALHALABI MM, Almokdad R
    The incidence of hepatitis B reactivation in patients receiving ustekinumab: a systematic review and proportional meta-analysis.
    Eur J Gastroenterol Hepatol. 2025;37:1-9.
    PubMed     Abstract available
    
    
    
26. ELFORD AT, Heldt R, Kamal S, Christensen B, et al
    Systematic review with meta-analysis of the effectiveness of subcutaneous biologics versus intravenous biologics in inflammatory bowel diseases.
    Eur J Gastroenterol Hepatol. 2025;37:47-54.
    PubMed     Abstract available
    
    
    November 2024
27. ALBSHESH A, Abend A, Yehuda RM, Mahajna H, et al
    Intestinal ultrasound accurately predicts future therapy failure in Crohn's disease patients in a biologics-induced remission.
    Eur J Gastroenterol Hepatol. 2024 Nov 8. doi: 10.1097/MEG.0000000000002883.
    PubMed     Abstract available
    
    
    
28. KOPPELMAN LJM, Maljaars PWJ, Voorneveld PW, van der Meulen-de Jong AE, et al
    Healthcare utilisation patterns and drivers amongst inflammatory bowel disease patients in the outpatient clinic.
    Eur J Gastroenterol Hepatol. 2024 Nov 5. doi: 10.1097/MEG.0000000000002880.
    PubMed     Abstract available
    
    
    
29. SUN Z, Li Y
    After nonsurgical treatment of penetrating Crohn's disease: indications for subsequent surgical intervention.
    Eur J Gastroenterol Hepatol. 2024;36:1353-1354.
    PubMed    
    
    
    
30. DURAK MB
    Nonsurgical approach in penetrating Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024;36:1352.
    PubMed    
    
    
    
31. FERREIRA AI, Lima Capela T, Arieira C, Xavier S, et al
    Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.
    Eur J Gastroenterol Hepatol. 2024;36:1314-1318.
    PubMed     Abstract available
    
    
    October 2024
32. SELIN KA, Andersson S, Bilen K, Strid H, et al
    Variation in nutritional therapy practices: results of a survey on nutritional management of severe inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Oct 29. doi: 10.1097/MEG.0000000000002872.
    PubMed     Abstract available
    
    
    
33. DAUNGSUPAWONG H, Wiwanitkit V
    Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet: correspondence.
    Eur J Gastroenterol Hepatol. 2024;36:1243.
    PubMed    
    
    
    September 2024
34. PAPATHANASIOU E, Kokkotis G, Axiaris G, Bellou G, et al
    Pregnancy outcomes in Greek women with inflammatory bowel disease: a longitudinal national retrospective study.
    Eur J Gastroenterol Hepatol. 2024 Sep 23. doi: 10.1097/MEG.0000000000002844.
    PubMed     Abstract available
    
    
    
35. SABHAN H, Bello F, Muhsen S, Borin A, et al
    Long-term real-world data of ustekinumab in ulcerative colitis: the Stockholm Ustekinumab Study (STOCUSTE).
    Eur J Gastroenterol Hepatol. 2024 Sep 20. doi: 10.1097/MEG.0000000000002854.
    PubMed     Abstract available
    
    
    
36. CESARO N, Valvano M, Monaco S, Stefanelli G, et al
    The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients.
    Eur J Gastroenterol Hepatol. 2024 Sep 12. doi: 10.1097/MEG.0000000000002842.
    PubMed     Abstract available
    
    
    
37. ALDIABAT M, Alhuneafat L, Al Ta'ani O, Altarawneh S, et al
    Inflammatory bowel disease and pulmonary embolism: a nationwide perspective.
    Eur J Gastroenterol Hepatol. 2024 Sep 12. doi: 10.1097/MEG.0000000000002851.
    PubMed     Abstract available
    
    
    
38. LOW ES, Greeve T, Boyapati RK, Moore GT, et al
    Characteristics of the Kono-S anastomosis in Crohn's disease patients using intestinal ultrasound.
    Eur J Gastroenterol Hepatol. 2024;36:1150-1152.
    PubMed    
    
    
    
39. COELHO R, Goncalves R, Mendes F, Macedo G, et al
    Gastroenterology healthcare in LGBTQ+ individuals.
    Eur J Gastroenterol Hepatol. 2024;36:1059-1067.
    PubMed     Abstract available
    
    
    August 2024
40. DU J, Xu F, Qiu X, Hu X, et al
    A novel computed tomography enterography radiomics combining intestinal and creeping fat features could predict surgery risk in patients with Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024 Aug 23. doi: 10.1097/MEG.0000000000002839.
    PubMed     Abstract available
    
    
    
41. NEAMTI L, Drugan TC, Drugan C, Silaghi C, et al
    Assessing seasonal variations of biomarkers in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024;36:993-999.
    PubMed     Abstract available
    
    
    July 2024
42. KAMEL AY, Johnson ZD, Hernandez I, Nguyen C, et al
    Micronutrient deficiencies in inflammatory bowel disease: an incidence analysis.
    Eur J Gastroenterol Hepatol. 2024 Jul 16. doi: 10.1097/MEG.0000000000002821.
    PubMed     Abstract available
    
    
    
43. KHALAF R, Sciberras M, Ellul P
    The role of the fecal microbiota in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002818.
    PubMed     Abstract available
    
    
    
44. NAQVI HA, Delungahawatta T, Atarere JO, Bandaru SK, et al
    Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002815.
    PubMed     Abstract available
    
    
    
45. KOLEHMAINEN S, Rautakorpi J, Loyttyniemi E, Af Bjorkesten CG, et al
    Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jul 8. doi: 10.1097/MEG.0000000000002816.
    PubMed     Abstract available
    
    
    
46. MILIOLI NJ, Fernandes MV, Correa TL, Antunes V, et al
    Vedolizumab versus ustekinumab in Crohn's disease with prior anti-tumor necrosis factor failure: an updated meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Jul 2. doi: 10.1097/MEG.0000000000002817.
    PubMed     Abstract available
    
    
    
47. OZTURK O, Celebi G, Duman UG, Kupcuk E, et al
    Short-chain fatty acid levels in stools of patients with inflammatory bowel disease are lower than those in healthy subjects.
    Eur J Gastroenterol Hepatol. 2024;36:890-896.
    PubMed     Abstract available
    
    
    June 2024
48. TORIS LD, Minsart CF, Husson CP, Franchimont DP, et al
    Lipopolysaccharide-binding protein in Crohn's disease patients: a promising noninvasive biomarker monitoring disease activity.
    Eur J Gastroenterol Hepatol. 2024 Jun 26. doi: 10.1097/MEG.0000000000002811.
    PubMed     Abstract available
    
    
    
49. FIERENS L, Bossuyt P, Baert F, Baert D, et al
    Development of a set of measurable outcome indicators for Flemish patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024 Jun 19. doi: 10.1097/MEG.0000000000002804.
    PubMed     Abstract available
    
    
    
50. CHHIBBA T, Wong ECL, Reinisch W, Targownik L, et al
    Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY.
    Eur J Gastroenterol Hepatol. 2024;36:704-711.
    PubMed     Abstract available
    
    
    May 2024
51. FREEMAN HJ
    Osteonecrosis (avascular necrosis) in inflammatory bowel disease: an extraintestinal clinical feature, not caused by corticosteroids.
    Eur J Gastroenterol Hepatol. 2024;36:503-504.
    PubMed    
    
    
    April 2024
52. YUAN B, Huang P, Yang M, Tang G, et al
    Intestinal ultrasound scan predicts corticosteroid failure and colectomy risk in patients with ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2024 Apr 17. doi: 10.1097/MEG.0000000000002780.
    PubMed     Abstract available
    
    
    
53. WESTON F, Carter B, Powell N, Young AH, et al
    Antidepressant treatment in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Apr 5. doi: 10.1097/MEG.0000000000002768.
    PubMed     Abstract available
    
    
    
54. SUN Z, Cao L, Chen Y, Zhu W, et al
    Long-term outcomes of intestinal penetrating Crohn's disease following successful nonoperative management.
    Eur J Gastroenterol Hepatol. 2024 Apr 5. doi: 10.1097/MEG.0000000000002775.
    PubMed     Abstract available
    
    
    
55. TEPES K, Hanzel J, Stubljar D, Strmsek K, et al
    Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
    Eur J Gastroenterol Hepatol. 2024 Apr 2. doi: 10.1097/MEG.0000000000002771.
    PubMed     Abstract available
    
    
    
56. D'HAENS G, Baert F, Danese S, Kobayashi T, et al
    Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
    Eur J Gastroenterol Hepatol. 2024;36:404-415.
    PubMed     Abstract available
    
    
    
57. BAI Y, Sun Y, He Q, Bai X, et al
    Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024;36:359-370.
    PubMed     Abstract available
    
    
    
58. KOSTEV K, Roderburg C, Loosen SH
    Inflammatory bowel disease is associated with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2024;36:498.
    PubMed    
    
    
    March 2024
59. ZAGOROWICZ E, Binowski G, Strzadala D, Pruszko C, et al
    Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland.
    Eur J Gastroenterol Hepatol. 2024 Mar 19. doi: 10.1097/MEG.0000000000002764.
    PubMed     Abstract available
    
    
    
60. ROKKAS T, Gisbert JP, Ekmektzoglou K, Dassopoulos T, et al
    Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Mar 12. doi: 10.1097/MEG.0000000000002751.
    PubMed     Abstract available
    
    
    
61. STEPHENS IJB, Murphy B, Burns L, McCawley N, et al
    Contemporary perioperative outcomes after total abdominal colectomy for ulcerative colitis in a tertiary referral centre.
    Eur J Gastroenterol Hepatol. 2024 Mar 11. doi: 10.1097/MEG.0000000000002755.
    PubMed     Abstract available
    
    
    
62. MOGILEVSKI T, Nguyen AL, Ajamian M, Smith R, et al
    Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2024;36:271-280.
    PubMed     Abstract available
    
    
    
63. FIORINO G, Colombel JF, Katsanos K, Mearin F, et al
    Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy.
    Eur J Gastroenterol Hepatol. 2024 Mar 1. doi: 10.1097/MEG.0000000000002740.
    PubMed     Abstract available
    
    
    February 2024
64. BHAYANA H, Sharma TK, Sharma A, Dhillon MS, et al
    Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2024 Feb 21. doi: 10.1097/MEG.0000000000002735.
    PubMed     Abstract available
    
    
    January 2024
65. KIRKIK D, Kalkanli Tas S, Tanoglu A
    Unraveling the blood microbiome: novel insights into inflammasome responses in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2024 Jan 22. doi: 10.1097/MEG.0000000000002695.
    PubMed     Abstract available
    
    
    December 2023
66. MANTZARIS GJ, Bressler B, Adsul S, Luo M, et al
    Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study.
    Eur J Gastroenterol Hepatol. 2023 Dec 27. doi: 10.1097/MEG.0000000000002690.
    PubMed     Abstract available
    
    
    
67. VIAZIS N, Manolakis A, Vraka M, Mylonas I, et al
    Anal defecatory function in ulcerative colitis patients after total proctocolectomy and ileal pouch-anal anastomosis: a prospective cohort study.
    Eur J Gastroenterol Hepatol. 2023 Dec 27. doi: 10.1097/MEG.0000000000002706.
    PubMed     Abstract available
    
    
    
68. SONNENBERG A, Duong HT, McCarty DJ, El-Serag HB, et al
    Concurrence of inflammatory bowel disease with multiple sclerosis or Hodgkin lymphoma.
    Eur J Gastroenterol Hepatol. 2023;35:1349-1353.
    PubMed     Abstract available
    
    
    
69. STJARNGRIM J, Ekbom A, Widman L, Hultcrantz R, et al
    Post-colonoscopy rectal cancer in Swedish patients with Crohn's disease 2001-2015: a population-based case review study.
    Eur J Gastroenterol Hepatol. 2023;35:1334-1340.
    PubMed     Abstract available
    
    
    November 2023
70. NGUYEN AL, Herath M, Burns M, Holt D, et al
    The value of whole-body dual-energy x-ray absorptiometry in assessing body composition in patients with inflammatory bowel disease: a prospective study.
    Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002675.
    PubMed     Abstract available
    
    
    October 2023
71. LIU C, Liu X, Shi H, Chen F, et al
    The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2023 Oct 18. doi: 10.1097/MEG.0000000000002670.
    PubMed     Abstract available
    
    
    
72. BARAUNA FSB, Magro DO, Miranda EF, Marcal GN, et al
    Correlation between trough levels of infliximab and postoperative endoscopic recurrence in Crohn's disease patients submitted to ileocolonic resections.
    Eur J Gastroenterol Hepatol. 2023 Oct 6. doi: 10.1097/MEG.0000000000002639.
    PubMed     Abstract available
    
    
    
73. VALIBOUZE C, Nachury M, Hambli S, Desreumaux P, et al
    Alternative to subtotal colectomy for pregnant woman with medically refractory acute severe ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:1230.
    PubMed    
    
    
    
74. JANSEN FM, den Broeder N, Lubeek SFK, Savelkoul EHJ, et al
    Cumulative thiopurine dosing and keratinocyte skin cancer in inflammatory bowel disease: a case-control study.
    Eur J Gastroenterol Hepatol. 2023;35:1123-1130.
    PubMed     Abstract available
    
    
    September 2023
75. FERRARO S, Cappello E, Bartolini C, Convertino I, et al
    Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002642.
    PubMed     Abstract available
    
    
    
76. ALHALABI M, Alaa Eddin K, Abbas A
    Therapeutic effects of biological treatments on AA amyloidosis associated with inflammatory bowel disease: a case report and literature review.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002649.
    PubMed     Abstract available
    
    
    
77. HONAP S, Irving PM, Samaan MA
    JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice.
    Eur J Gastroenterol Hepatol. 2023 Sep 18. doi: 10.1097/MEG.0000000000002650.
    PubMed     Abstract available
    
    
    
78. NERI B, D'Agostini G, Salvatori S, Mossa M, et al
    Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
    Eur J Gastroenterol Hepatol. 2023;35:948-954.
    PubMed     Abstract available
    
    
    August 2023
79. ZHANG T, Zhang QD, Jin T, Li WJ, et al
    Is histological healing more clinically valuable than endoscopic healing in Crohn's disease?
    Eur J Gastroenterol Hepatol. 2023 Aug 14. doi: 10.1097/MEG.0000000000002624.
    PubMed     Abstract available
    
    
    
80. TSAFARIDOU M, Augoustaki A, Koutroubakis I
    Lymphogranuloma venereum and CMV co-infection mimicking ulcerative proctitis in a non-immunocompromised patient.
    Eur J Gastroenterol Hepatol. 2023;35:921-922.
    PubMed    
    
    
    
81. HUANG Y, Su Y, Qin R, Wang L, et al
    Mechanism by which oleracein E alleviates TNBS-induced ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023;35:854-864.
    PubMed     Abstract available
    
    
    July 2023
82. LYKOWSKA-SZUBER L, Walczak M, Dobrowolska A, Skrzypczak-Zielinska M, et al
    Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002618.
    PubMed     Abstract available
    
    
    
83. ZHAN Y, Cheng X, Mei P, Wu J, et al
    Risk and incidence of colorectal stricture progressing to colorectal neoplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2023 Jul 31. doi: 10.1097/MEG.0000000000002614.
    PubMed     Abstract available
    
    
    
84. BOUSTANY A, Rahhal R, Mitri J, Onwuzo S, et al
    The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review.
    Eur J Gastroenterol Hepatol. 2023 Jul 11. doi: 10.1097/MEG.0000000000002607.
    PubMed     Abstract available
    
    
    May 2023
85. KONSTANTINOU CS, Korantzopoulos P, Fousekis FS, Katsanos KH, et al
    Inflammatory bowel disease and atrial fibrillation: a contemporary overview.
    Eur J Gastroenterol Hepatol. 2023 May 8. doi: 10.1097/MEG.0000000000002562.
    PubMed     Abstract available
    
    
    
86. HASSAN EA, Abdel Rehim ASE, Ahmed AO, Salim SMAE, et al
    Current insight into enteropathogens in flare-up ulcerative colitis. An observational study.
    Eur J Gastroenterol Hepatol. 2023 May 3. doi: 10.1097/MEG.0000000000002563.
    PubMed     Abstract available
    
    
    
87. PRENTICE RE, Wright EK, Flanagan E, Kamm MA, et al
    Evaluation and management of ileal pouch-anal anastamosis (IPAA) complications in pregnancy, and the impacts of an IPAA on fertility.
    Eur J Gastroenterol Hepatol. 2023;35:609-612.
    PubMed     Abstract available
    
    
    April 2023
88. CHAHAL JK, Sriranganathan D, Poo S, Lo SW, et al
    Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's disease.
    Eur J Gastroenterol Hepatol. 2023 Apr 11. doi: 10.1097/MEG.0000000000002552.
    PubMed     Abstract available
    
    
    
89. PRINCIPI M, Macaluso FS, Todeschini A, Facciotti F, et al
    Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD).
    Eur J Gastroenterol Hepatol. 2023 Apr 4. doi: 10.1097/MEG.0000000000002550.
    PubMed     Abstract available
    
    
    March 2023
90. NOVAK G, Sever N, Hanzel J, Kozelj M, et al
    Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2023 Mar 20. doi: 10.1097/MEG.0000000000002543.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.